Drug Device Combination Products Market, Growth Report 2032

Drug Device Combination Products Market Size - By Product (Drug-eluting Stents, Infusion Pumps, Photodynamic Therapy, Wound Care Combination Product, Prefilled Syringes, Drug-eluting Balloons, Inhalers), Application, End-use & Global Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp;Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp;Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp;Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp;Forecast model

1.5&nbsp;&nbsp;&nbsp;Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp;Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights 

3.1&nbsp;&nbsp;&nbsp;Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp;Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing demand for minimally invasive drug delivery devices

3.2.1.2&nbsp;&nbsp;&nbsp; Technological advancements

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing prevalence of chronic diseases

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost associated with drug device combination products

3.2.2.2&nbsp;&nbsp;&nbsp; Technical challenges in drug delivery

3.3&nbsp;&nbsp;&nbsp;Growth potential analysis

3.4&nbsp;&nbsp;&nbsp;Technological landscape

3.5&nbsp;&nbsp;&nbsp;Regulatory landscape

3.6&nbsp;&nbsp;&nbsp;Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp;PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp;Introduction

4.2&nbsp;&nbsp;&nbsp;Company matrix analysis

4.3&nbsp;&nbsp;&nbsp;Company market share analysis

4.4&nbsp;&nbsp;&nbsp;Strategic outlook matrix

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp;Key trends

5.2&nbsp;&nbsp;&nbsp;Drug-eluting stents

5.2.1&nbsp;&nbsp;&nbsp; Coronary drug-elating stents

5.2.2&nbsp;&nbsp;&nbsp; Peripheral drug-eluting stents

5.3&nbsp;&nbsp;&nbsp;Infusion pumps

5.3.1&nbsp;&nbsp;&nbsp; Implantable infusion pumps

5.3.2&nbsp;&nbsp;&nbsp; Insulin infusion pumps

5.3.3&nbsp;&nbsp;&nbsp; Patient-controlled analgesia pumps

5.3.4&nbsp;&nbsp;&nbsp; Ambulatory infusion pumps

5.3.5&nbsp;&nbsp;&nbsp; Volumetric infusion pumps

5.3.6&nbsp;&nbsp;&nbsp; Disposable infusion pumps

5.4&nbsp;&nbsp;&nbsp;Photodynamic therapy

5.5&nbsp;&nbsp;&nbsp;Wound care combination product

5.6&nbsp;&nbsp;&nbsp;Prefilled syringes

5.6.1&nbsp;&nbsp;&nbsp; Single-chamber prefilled syringes

5.6.2&nbsp;&nbsp;&nbsp; Dual-chamber prefilled syringes

5.6.3&nbsp;&nbsp;&nbsp; Customized prefilled syringes

5.7&nbsp;&nbsp;&nbsp;Drug-eluting balloons

5.7.1&nbsp;&nbsp;&nbsp; Coronary drug-eluting balloons

5.7.2&nbsp;&nbsp;&nbsp; Peripheral drug-eluting balloons

5.8&nbsp;&nbsp;&nbsp;Nebulizers

5.9&nbsp;&nbsp;&nbsp;Inhalers

5.9.1&nbsp;&nbsp;&nbsp; Drug powdered inhalers (DPIs)

5.9.2&nbsp;&nbsp;&nbsp; Metered dose inhalers (MDIs)

5.9.3&nbsp;&nbsp;&nbsp; Soft mist inhalers (SMIs)

5.10&nbsp;&nbsp;&nbsp;Transdermal delivery systems

5.10.1&nbsp;&nbsp;&nbsp; Active transdermal systems

5.10.2&nbsp;&nbsp;&nbsp; Passive transdermal systems

5.11&nbsp;&nbsp;&nbsp;Orthopedic combination products

5.11.1&nbsp;&nbsp;&nbsp; Bone graft implants

5.11.2&nbsp;&nbsp;&nbsp; Antibiotic loaded bone cement

5.12&nbsp;&nbsp;&nbsp;Antimicrobial catheters

5.12.1&nbsp;&nbsp;&nbsp; Urological catheters

5.12.2&nbsp;&nbsp;&nbsp; Cardiovascular catheters

5.12.3&nbsp;&nbsp;&nbsp; Other catheters

5.13&nbsp;&nbsp;&nbsp;Other products

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp;Key trends

6.2&nbsp;&nbsp;&nbsp;Cardiovascular disorders

6.3&nbsp;&nbsp;&nbsp;Diabetes

6.4&nbsp;&nbsp;&nbsp;Respiratory problems

6.5&nbsp;&nbsp;&nbsp;Cancer treatment

6.6&nbsp;&nbsp;&nbsp;Antimicrobial application

6.7&nbsp;&nbsp;&nbsp;Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-use, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp;Key trends

7.2&nbsp;&nbsp;&nbsp;Hospitals and clinics

7.3&nbsp;&nbsp;&nbsp;Ambulatory surgical centers

7.4&nbsp;&nbsp;&nbsp;Home care settings

7.5&nbsp;&nbsp;&nbsp;Other end-users

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp;Key trends

8.2&nbsp;&nbsp;&nbsp;North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp;Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp;Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp;Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp;Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles 

9.1&nbsp;&nbsp;&nbsp;Abbott Laboratories

9.2&nbsp;&nbsp;&nbsp;AbbVie, Inc.

9.3&nbsp;&nbsp;&nbsp;Alcon, Inc.

9.4&nbsp;&nbsp;&nbsp;Bausch Health Companies Inc

9.5&nbsp;&nbsp;&nbsp;Baxter International Inc.

9.6&nbsp;&nbsp;&nbsp;Bayer AG

9.7&nbsp;&nbsp;&nbsp;Becton, Dickinson and Company

9.8&nbsp;&nbsp;&nbsp;Boston Scientific Corporation

9.9&nbsp;&nbsp;&nbsp;GlaxoSmithKline plc

9.10&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

9.11&nbsp;&nbsp;&nbsp; Kaleo, Inc.

9.12&nbsp;&nbsp;&nbsp; Medtronic plc

9.13&nbsp;&nbsp;&nbsp; Novartis AG

9.14&nbsp;&nbsp;&nbsp; SINOMED

9.15&nbsp;&nbsp;&nbsp; Smith &amp; Nephew plc

9.16&nbsp;&nbsp;&nbsp; Teleflex Incorporated

9.17&nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd.

&nbsp;&nbsp;&nbsp; &nbsp;

Drug Device Combination Products Market

Get a free sample of this report